Skip to main content

2 Result(s)

within Li-Na Tang Remove this filter Medicine & Public Health Remove this filter Pharmacology/Toxicology Remove this filter

and

  1. No Access

    Article

    Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis

    To gain a better understanding of the overall incidence and risk of hypertension in cancer patients who receive pazopanib and to compare the differences in incidence among sorafenib, sunitinib, and pazopanib.

    Wei-**ang Qi, Feng Lin, Yuan-jue Sun, Li-Na Tang… in Cancer Chemotherapy and Pharmacology (2013)

  2. No Access

    Article

    Risk of Hypertension in Cancer Patients Treated with Aflibercept: A Systematic Review and Meta-Analysis

    Aflibercept is currently approved as second-line treatment for patients with metastatic colorectal cancer, and its application in other types of tumors is undergoing clinical evaluation. Hypertension is one of...

    Wei-**ang Qi, Zan Shen, Li-Na Tang, Yang Yao in Clinical Drug Investigation (2014)